CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 63.8 CNY -0.13% Market Closed
Market Cap: 7.3B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

Net Margin
CanSino Biologics Inc

-96.2%
Current
-132%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-96.2%
=
Net Income
-720.1m
/
Revenue
748.5m

Net Margin Across Competitors

Country CN
Market Cap 7.3B CNY
Net Margin
-96%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 372B USD
Net Margin
17%
Country US
Market Cap 257.3B USD
Net Margin
19%
Country CH
Market Cap 201.7B CHF
Net Margin
20%
Country UK
Market Cap 163B GBP
Net Margin
13%
Country CH
Market Cap 179.6B CHF
Net Margin
35%
Country US
Market Cap 146B USD
Net Margin
7%
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
7.3B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
66.95 CNY
Undervaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-96.2%
=
Net Income
-720.1m
/
Revenue
748.5m
What is the Net Margin of CanSino Biologics Inc?

Based on CanSino Biologics Inc's most recent financial statements, the company has Net Margin of -96.2%.